| 靶点: |
β-tubulin polymerization |
| 体内研究: |
ValecobμLin (5 mg/kg;腹膜内注射;在第 2、6、10 和 14 天给药;雄性 BALB/C nu/nu 小鼠) 处理在各种人类肿瘤异种移植模型中显示出显著的抗肿瘤功效。 |
| 参考文献: |
1. Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53(17):6337-54. 2. Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272(2):417-26. |
| 保存条件: |
-80℃,干燥(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.745 ml |
8.725 ml |
17.45 ml |
| 5 mM |
0.349 ml |
1.745 ml |
3.49 ml |
| 10 mM |
0.175 ml |
0.873 ml |
1.745 ml |
| 50 mM |
0.035 ml |
0.175 ml |
0.349 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |